Michael Martin

The translational landscape of mTOR signalling steers cancer initiation and metastasis

Nicholas T. Ingolia, J. Weissman, K. Shokat, 2012, Nature.

Abstract CT-02: A phase I, open label, dose escalation study of oral mammalian target of rapamycin inhibitor INK128 administered by intermittent dosing regimens in patients with advanced malignancies

J. Tabernero, C. Rommel, H. Burris, 2012 .

Abstract B148: INK128 is a potent and selective TORC1/2 inhibitor with broad oral antitumor activity

Shunyou Wang, Katrina Chan, C. Rommel, 2009 .

Abstract A171: A potent and selective PI3K inhibitor, INK1117, targets human cancers harboring oncogenic PIK3CA mutations.

Shunyou Wang, Katrina Chan, C. Rommel, 2011 .

Improving Grant Application Peer Review for the NIEHS

D. A. Schwartz, S. Chattopadhyay, Kamini Singh, 2006, Environmental health perspectives.

Abstract 5588: A phase I, open label, dose escalation study of an oral mammalian target of rapamycin inhibitor INK128 administered once daily in patients with advanced malignancies

J. Tabernero, C. Rommel, P. Klein, 2012 .

Abstract 4486: INK128, a novel TORC1/2 inhibitor with potent oral antitumor activity in preclinical models of renal cancer

Shunyou Wang, Katrina Chan, C. Rommel, 2011 .